| Literature DB >> 25761230 |
Silvia Panzeri1, Simone Zanella, Daniela Arosio, Leila Vahdati, Alberto Dal Corso, Luca Pignataro, Mayra Paolillo, Sergio Schinelli, Laura Belvisi, Cesare Gennari, Umberto Piarulli.
Abstract
The cyclo[DKP-isoDGR] peptidomimetics 2-5, containing bifunctional diketopiperazine (DKP) scaffolds that differ in the configuration of the two DKP stereocenters and in the substitution at the DKP nitrogen atoms, were prepared and examined in vitro in competitive binding assays with purified αv β3 and αv β5 integrin receptors. IC50 values ranged from low nanomolar (ligand 3) to submicromolar with αv β3 integrin. The biological activities of ligands cyclo[DKP3-RGD] 1 and cyclo[DKP3-isoDGR] 3, bearing the same bifunctional DKP scaffold and showing similar αV β3 integrin binding values, were compared in terms of their cellular effects in human U373 glioblastoma cells. Compounds 1 and 3 displayed overlapping inhibitory effects on the FAK/Akt integrin activated transduction pathway and on integrin-mediated cell infiltration processes, and qualify therefore, despite the different RGD and isoDGR sequences, as integrin antagonists. Both compounds induced apoptosis in glioma cells after 72 hour treatment.Entities:
Keywords: cell adhesion; drug design; drug discovery; peptidomimetics; phosphorylation
Mesh:
Substances:
Year: 2015 PMID: 25761230 DOI: 10.1002/chem.201406567
Source DB: PubMed Journal: Chemistry ISSN: 0947-6539 Impact factor: 5.236